Enhancement of protective immune responses induced by toxoplasma gondii dense granule antigen 7 (GRA7) against toxoplasmosis in mice using a prime-boost vaccination strategy

Vaccine

Volumn 30, Issue 38, 2012, Pages 5631-5636

  Min, Juan ^a   Qu, Daofeng ^b   Li, Changzheng ^c   Song, Xilin ^c   Zhao, Qunli ^a   Li, Xin ai ^d   Yang, Yongmei ^e   Liu, Qi ^a   He, Shenyi ^a   Zhou, Huaiyu ^a  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG GONGSHANG UNIVERSITY   (China)

^c SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^d Jinan Nursing Professional College   (China)

^e SHANDONG UNIVERSITY   (China)

Author keywords

GRA7; Mice; Prime boost vaccination; Toxoplasma gondii

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G2A ANTIBODY; PEGFP GRA7 DNA VACCINE; PROTOZOAL PROTEIN; RECOMBINANT PROTEIN DENSE GRANULE ANTIGEN 7; TOXOPLASMA GONDII VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMORAL IMMUNITY; MOUSE; NONHUMAN; PRIME BOOST VACCINATION; PRIORITY JOURNAL; TOXOPLASMA GONDII; TOXOPLASMOSIS; TREATMENT OUTCOME; VACCINATION;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; FEMALE; IMMUNOGLOBULIN G; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; SURVIVAL ANALYSIS; TOXOPLASMOSIS, ANIMAL; VACCINATION; VACCINES, DNA; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 84864766099     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.06.081     Document Type: Article

References (35)

1. Dubey J.P., Su C. Population biology of Toxoplasma gondii: what's out and where did they come from. Mem Inst Oswaldo Cruz 2009, 104(2):190-195.
2. Weiss L.M., Dubey J.P. Toxoplasmosis: a history of clinical observations. Int J Parasitol 2009, 39(8):895-901.
3. Montoya J.G., Liesenfeld O. Toxoplasmosis. Lancet 2004, 363(9425):1965-1976.
4. Kur J., Holec-Gasior L., Hiszczyńska-Sawicka E. Current status of toxoplasmosis vaccine development. Expert Rev Vaccines 2009, 8(6):791-808.
5. Bhopale G.M. Development of a vaccine for toxoplasmosis: current status. Microbes Infect 2003, 5(5):457-462.
6. Buxton D. Toxoplasmosis: the first commercial vaccine. Parasitol Today 1993, 9(9):335-337.
7. Ogra P.L., Faden H.S., Abraham R., Duffy L.C., Sun M., Minor P.D. Effect of prior immunity on the shedding of virulent revertant virus in feces after oral immnunization with live attenuated poliovirus vaccines. J Infect Dis 1991, 164(1):191-194.
8. Mishima M., Xuan X., Yokoyama N., Igarashi I., Fujisaki K., Nagasawa H., et al. Recombinant feline herpesvirus type 1 expressing Toxoplasma gondii ROP2 antigen inducible protective immunity in cats. Parasitol Res 2002, 88(2):144-149.
9. Bermúdez-Humarán L.G., Kharrat P., Chatel J.M., Langella P. Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines. Microb Cell Fact 2011, 10(S1):S4.
10. Thomas W.R., Hales B.J., Smith W.A. Genetically engineered vaccines. Curr Allergy Asthma Rep 2005, 5(3):197-203.
11. Jung C., Lee C.Y., Grigg M.E. The SRS superfamily of Toxoplasma surface proteins. Int J Parasitol 2004, 34(3):285-296.
12. Lecordier L., Moleon-Borodowsky I., Dubremetz J.F., Tourvieille B., Mercier C., Deslée D., et al. Characterization of a dense granule antigen of Toxoplasma gondii (GRA6) associated to the network of the parasitophorous vacuole. Mol Biochem Parasitol 1995, 70(1-2):85-94.
13. Tilley M., Fichera M.E., Jerome M.E., Roos D.S., White M.W. Toxoplasma gondii sporozoites form a transient parasitophorous vacuole that is impermeable and contains only a subset of dense-granule proteins. Infect Immun 1997, 65(11):4598-4605.
14. Pfrepper K.I., Enders G., Gohl M., Krczal D., Hlobil H., Wassenberg D., et al. Seroreactivity to and avidity for recombinant antigens in toxoplasmosis. Clin Diagn Lab Immunol 2005, 12(8):977-982.
15. Neudeck A., Stachelhaus S., Nischik N., Striepen B., Reichmann G., Fischer H.G. Expression variance, biochemical and immunological properties of Toxoplasma gondii dense granule protein GRA7. Microbes Infect 2002, 4(6):581-590.
16. Hiszczyńska-Sawicka E., Oleogonekdzka G., Holec-Gaogoneksior L., Li H., Xu J.B., Sedcole R., et al. Evaluation of immune responses in sheep induced by DNA immunization with genes encoding GRA1, GRA4, GRA6 and GRA7 antigens of Toxoplasma gondii. Vet Parasit 2011, 177(3-4):281-289.
17. Jongert E., De Craeye S., Dewit J., Huygen K. GRA7 provides protective immunity in cocktail DNA vaccines against Toxoplasma gondii. Parasite Immunol 2007, 29(9):445-453.
18. Verhelst D., De Craeye S., Dorny P., Melkebeek V., Goddeeris B., Cox E., et al. IFN-γ expression and infectivity of Toxoplasma infected tissues are associated with an antibody response against GRA7 in experimentally infected pigs. Vet Parasitol 2011, 179(1-3):14-21.
19. Zhang G., Huong V.T., Battur B., Zhou J., Zhang H., Liao M., et al. A heterologous prime-boost vaccination regimen using DNA and a vaccinia virus, both expressing GRA4, induced protective immunity against Toxoplasma gondii infection in mice. Parasitology 2007, 134(Pt 10):1339-1346.
20. Laguía-Becher M., Martín V., Kraemer M., Corigliano M., Yacono M.L., Goldman A., et al. Effect of codon optimization and subcellular targeting on Toxoplasma gondii antigen SAG1 expression in tobacco leaves to use in subcutaneous and oral immunization in mice. BMC Biotechnol 2010, 10:52.
21. Shang L., Liu Q., Liu W., Men J., Gao S., Jiang L., et al. Protection in mice immunized with a heterologous prime-boost regimen using DNA and recombinant pseudorabies expressing TgSAG1 against Toxoplasma gondii challenge. Vaccine 2009, 27(21):2741-2745.
22. Zhou H., Min J., Zhao Q., Gu Q., Cong H., Li Y., et al. Protective immune response against Toxoplasma gondii elicited by a recombinant DNA vaccine with a novel genetic adjuvant. Vaccine 2012, 30(10):1800-1806.
23. Mercier C., Adjogble K.D., Däubener W., Delauw M.F. Dense granules: are they key organelles to help understand the parasitophorous vacuole of all Apicomplexa parasites?. Int J Parasitol 2005, 35(8):829-849.
24. Robinson H.L. DNA vaccines: basic mechanism and immune responses (review). Int J Mol Med 1999, 4(5):549-555.
25. Liang R., van den Hurk J.V., Zheng C., Yu H., Pontarollo R.A., Babiuk L.A., et al. Immunization with plasmid DNA encoding a truncated, secreted form of the bovine viral diarrhea virus E2 protein elicits strong humoral and cellular immune responses. Vaccine 2005, 23(45):5252-5262.
26. Martin J.E., Sullivan N.J., Enama M.E., Gordon I.J., Roederer M., Koup R.A., et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol 2006, 13(11):1267-1277.
27. Alekseeva E., Sominskaya I., Skrastina D., Egorova I., Starodubova E., Kushners E., et al. Enhancement of the expression of HCV core gene does not enhance core-specific immune response in DNA immunization: advantages of the heterologous DNA prime, protein boost immunization regimen. Genet Vaccines Ther 2009, 7(7):1-17.
28. Woodland D.L. Jump-starting the immune system: prime-boosting comes of age. Trends Immunol 2004, 25:98-104.
29. Schirmbeck R., Reimann J. Alternative processing of endogenous or exogenous antigens extends the immunogenic, H-2 class I-restricted peptide repertoire. Mol Immunol 2002, 39(3-4):249-259.
30. Mosmann T.R., Li L., Hengartner H., Kagi D., Fu W., Sad S. Differentiation and functions of T cell subsets. Ciba Found Symp 1997, 204:148-154.
31. Pulendran B. Modulating TH1/TH2 responses with microbes, dendritic cells, and pathogen recognition receptors. Immunol Res 2004, 29(1-3):187-196.
32. + T lymphocytes in IFN-gamma production and protective immunity induced by an attenuated Toxoplasma gondii vaccine. J Immunol 1991, 146(1):286-292.
33. Jongert E., Lemiere A., Van Ginderachter J., De Craeye S., Huygen K., D'Souza S. Functional characterization of in vivo effector CD4(+) and CD8(+) T cell responses in acute Toxoplasmosis: an interplay of IFN-gamma and cytolytic T cells. Vaccine 2010, 28(13):2556-2564.
34. Yap G.S., Sher A. Cell-mediated immunity to Toxoplasma gondii: initiation, regulation and effector function. Immunobiology 1999, 201(2):240-247.
35. Johnson L.L., Lanthier P., Hoffman J., Chen W. Vaccination protects B cell-deficient mice against an oral challenge with mildly virulent Toxoplasma gondii. Vaccine 2004, 22(29-30):4054-4061.